What is the diagnostic approach for tropical pulmonary eosinophilia?

Diagnosis of Tropical Pulmonary Eosinophilia

Tropical pulmonary eosinophilia (TPE) is diagnosed based on: residence in a filarial endemic area, nocturnal paroxysmal cough with wheeze/dyspnea, absolute eosinophil count >3,300 cells/mm³, markedly elevated serum IgE (>1,000 IU/mL), positive filarial serology, and dramatic clinical/hematological response to diethylcarbamazine (DEC). 1, 2

Essential Diagnostic Criteria

The diagnosis rests on the following mandatory elements 1, 2:

• Geographic exposure: Patient must have resided in or traveled to filarial endemic areas (Africa, West Pacific, Caribbean, parts of South America, India, SE Asia)
• Clinical presentation: Nocturnal cough (worse at night), wheeze, dyspnea, often misdiagnosed as asthma 1, 3
• Absolute eosinophil count: Must be >3,300 cells/mm³ (not just >3,000) 2
  • This threshold was established because eosinophil counts below 3,225 showed marked fluctuation after DEC treatment, while counts >3,600 showed stable response
  • All patients with counts >3,600 responded to DEC in validation studies
• Serum IgE: Extraordinarily high levels, typically >1,000 IU/mL 3, 4
• Response to DEC: Dramatic clinical improvement and eosinophil count reduction (mean 92.5% decrease at 3 months) confirms diagnosis 2

Supporting Investigations

These findings support but are not required for diagnosis 1, 2:

• Chest radiograph: Bilateral interstitial mottling or infiltrates (present in only 45.5% of cases) 2
• ESR: Elevated in 80% of cases 2
• Filarial antibody test (FAT): Positive in only 30% of cases—low sensitivity, not reliable 2
• Lung function tests: Predominantly restrictive pattern, may have obstructive features 4
• Nocturnal blood microscopy: Typically negative for microfilariae (TPE is occult filariasis) 1

Critical Diagnostic Pitfall

The filarial antibody test has poor sensitivity (only 30%) and should NOT be relied upon to exclude TPE 2. The diagnosis is primarily clinical, supported by the eosinophil count threshold and confirmed by therapeutic response to DEC.

Pre-Treatment Safety Assessment

Before initiating DEC treatment, you must exclude co-infections 1:

• Onchocerciasis: Perform skin snips and slit lamp examination if patient traveled to co-endemic regions
  • DEC can cause severe reactions including blindness in onchocerciasis co-infection
  • If negative, give test dose of 50 mg DEC to check for Mazzotti reaction
• Loiasis: Check day blood microscopy for microfilariae
  • If microfilariae >1,000/mL, DEC can cause fatal encephalopathy
  • Must reduce microfilarial load with prednisolone and albendazole first
• Strongyloidiasis: Screen before using corticosteroids (if needed for symptom control)

Diagnostic Algorithm

1. Screen for geographic exposure to filarial endemic areas
2. Confirm absolute eosinophil count >3,300 cells/mm³
3. Measure serum IgE (expect >1,000 IU/mL)
4. Obtain chest radiograph (may show bilateral infiltrates)
5. Check ESR (usually elevated)
6. Perform nocturnal blood microscopy (typically negative, distinguishes from other filariasis)
7. Exclude co-infections (onchocerciasis, loiasis, strongyloidiasis) before treatment
8. Initiate DEC and monitor response (clinical improvement and eosinophil reduction confirms diagnosis)

Atypical Presentations

Rare cases may present with 3:

• Cor pulmonale
• Cystic lung disease
• Acute respiratory distress mimicking severe asthma

Some patients with eosinophil counts between 53-2,000 cells/mm³ may represent atypical TPE if they respond to DEC, though this remains controversial 2.

Treatment Confirmation

The definitive diagnostic confirmation is therapeutic response to DEC 1, 2: sustained clinical benefit, improved lung function, and eosinophil count reduction maintained for at least 15 months post-treatment. Approximately 15-20% may relapse and require a second course 3.